Additive Manufacturing for Oral Drug Delivery

News, Resources | February 27, 2026

Aprecia’s 3DP technology platforms deliver technical and operational advantages for biotech companies seeking rapid, flexible, and individualized oral drug delivery solutions. Additive manufacturing (AM) is proven, scalable, and regulatory-accepted, positioning it as a strategic asset for next-generation therapies.

Rethinking Tablet Manufacturing: The Power of Additive Manufacturing

Traditional tablet manufacturing relies on fixed, bulk processes that limit flexibility and personalization. In contrast, Aprecia’s AM technology — specifically , powder-liquid deposition (binder jetting)— constructs tablets layer-by-layer from digital 3D models. This approach enables precise spatial control over active pharmaceutical ingredients (APIs) and excipients, allowing for complex, multi-phase structures and rapid prototyping, all within a single, scalable GMP process.

Key technical advantages include:

  • Uniform powder layer deposition and precise application of picoliter-scale liquid droplets for targeted binding and drug delivery.
  • Real-time adjustment of tablet density, porosity, and drug release kinetics, supporting everything from rapid disintegration to controlled release.
  • Continuous process monitoring and powder recycling for efficiency and quality assurance.

Rapidly Disintegrating Tablets

Aprecia’s Zipdose® technology produces highly porous, robust tablets that disintegrate in seconds regardless of size or drug load. This technology, validated at commercial scale with the FDA-approved Spritam®, enables high-dose medications to be delivered in a single, palatable unit, improving dosing convenience and compliance for both pediatric and adult patients. The continuous, open-bed manufacturing process integrates powder deposition, printing, drying, inspection, and blister packaging, ensuring speed and quality at every step.

Individualized and Adaptive Therapies

Aprecia’s 3D-printed tablet platform is designed for the future of personalized medicine. By printing tablets directly into blister cavities, the platform enables:

  • Multi-layer tablets with distinct APIs or release profiles
  • Dose titration and patient-specific regimens, such as adaptive escalation for GLP-1 analogues
  • Integrated track -and-trace at the tablet level utilizing robust real-time quality

This flexibility supports distributed and point-of-care manufacturing, aligning with FDA’s vision for resilient supply chains and individualized therapies. The platform can tailor each tablet’s composition to patient needs, opening new possibilities for flexible dosing and improved clinical outcomes.

Accelerating Product Development and Market Impact

As a Contract Development and Manufacturing Organization (CDMO), Aprecia partners with biotech innovators to:

  • Rapidly iterate proof-of-concept formulations using minimal API
  • Seamlessly scale AM processes from bench to GMP clinical supply, while maintaining precision through commercial scale 3D-printing
  • Integrate sponsor knowledge for accelerated, de-risked development
  • Navigate regulatory pathways, leveraging over 15 years of FDA engagement

Aprecia’s AM enables novel product profiles— such as high-dose, palatable, rapidly disintegrating tablets for populations with swallowing difficulties and supports flexible dosing and adaptive packaging for better compliance and outcomes. Distributed manufacturing models further enhance supply chain resilience and enable real-time therapy adjustments.

“In today’s world, innovators must accelerate complex product development and respond to patient needs without sacrificing quality or compliance” said Andrew Karazim, Chief Commercial Officer, Aprecia Pharmaceuticals. “Aprecia’s advanced 3DP technology empowers pharmaceutical companies to break through traditional limitations by delivering tailored, embedded functionalities with precision and efficiency at any scale. This is how we help the pharmaceutical industry move beyond expectations and redefine what’s possible in oral drug delivery.”

The Future: Transformational Opportunities for Patients and Pharma

Aprecia’s 3DP technology platforms are more than technical innovations — they are strategic assets for the future of oral drug delivery. By enabling precise, flexible, and scalable manufacturing, these platforms empower pharma companies to bring differentiated, high-value products to market faster, while improving patient experiences and outcomes.

Additive manufacturing is not just a new way to make tablets but a new way to think about medicine. To learn more about Aprecia’s capabilities and how they can support your organization, visit aprecia.com/capabilities